Back to top
more

Arvinas (ARVN)

(Delayed Data from NSDQ)

$27.14 USD

27.14
840,209

-0.61 (-2.20%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $27.18 +0.04 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?

by Zacks Equity Research

Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.

Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.

Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?

by Zacks Equity Research

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.

What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock

by Zacks Equity Research

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arvinas, Inc. (ARVN) and ImmunoGen (IMGN) have performed compared to their sector so far this year.

Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study

by Zacks Equity Research

Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients.

Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 145.5% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Arvinas, Inc. (ARVN) points to a 165.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Arvinas, Inc. (ARVN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat

by Zacks Equity Research

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise.

Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?

by Zacks Equity Research

Arvinas, Inc. (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 25.15% and 67.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.48% and 5.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 9.09% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -50% and 8.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.53% and 31.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Why Arvinas (ARVN) Might Surprise This Earnings Season

by Zacks Equity Research

Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.